Program in Women’s Oncology, Women & Infants Hospital, Providence, RI (P.D., C.M.); The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, United Kingdom (S.B.); University of Milan-Bicocca and Istituto Europeo di Oncologia IRCCS, Milan (N.C.); Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome (G.S.), Italy; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea (B.-G.K.); Gynaecologic Cancer Programme, Vall d’Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain (A. Oaknin); University of New South Wales Clinical School, Prince of Wales Hospital, Randwick, New South Wales, Australia (M.F.); St Petersburg City Oncology Dispensary, St Petersburg, Russia (A. Lisyanskaya); Institut Bergonié, Comprehensive Cancer Center, Bordeaux (A.F.); Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens, Paris (A.F., A. Leary); Institut Gustave-Roussy, Villejuif (A. Leary), France; The Netherlands Cancer Institute, Amsterdam, the Netherlands (G.S.S.); Cancer Research UK Scotland Center, University of Edinburgh, Edinburgh, United Kingdom (C.G.); Princess Margaret Cancer Center, Toronto, ON, Canada (A. Oza); Clínica Universidad de Navarra, Madrid (A.G.-M.); Program In Solid Tumours, CIMA, Pamplona (A.G.-M.), Spain; Memorial Sloan Kettering Cancer Center, New York, NY (C.A.); Froedtert and the Medical College of Wisconsin, Milwaukee, WI (W.B.); Dana-Farber Cancer Institute, Boston, MA (J.L.); Biostatistics, Oncology Biometrics, Oncology R&D, AstraZeneca, Cambridge, United Kingdom (J.M.); Global Medicines Development, Oncology, AstraZeneca, Gaithersburg, MD (E.S.L.); Oncology R&D, Late-stage Development, AstraZeneca, Cambridge, United Kingdom (M.-L.A.-S.); and Stephenson Oklahoma Cancer Center, Oklahoma City, OK (K.N.M.)
